Program
Famotidine
Also written as “Atazanavir+Ritonavir+Tenofovir+Famotidine”, “Famotidine Tablets, 40 mg” and “Atazanavir/Ritonavir + Famotidine”.
Its studies are mostly in COVID-19 · HIV Infections · Ulcer · Arthritis, Juvenile · Heartburn, led by 8 companies.
Drug pageFamotidine: every studyMany companies study it; this page follows only the 13 they lead. All 52 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Leidos Life Sciencesits history only | 30 open or running | phase 2since Oct 7, 2021 | Oct 7, 2021 | none ahead |
| Amgenits history only | 20 open or running | phase 4since Mar 20, 2012 | Mar 19, 2007 | none ahead |
| Perrigoits history only | 20 open or running | phase 1since Dec 3, 2008 | Dec 3, 2008 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | no phasesince Feb 18, 2010 | Feb 18, 2010 | none ahead |
| Astellas Pharmaits history only | 10 open or running | phase 3since Sep 1, 2005 | Sep 1, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 10 open or running | phase 1since Jan 12, 2012 | Jan 12, 2012 | none ahead |
| drpykessupplements.comits history only | 10 open or running | phase 4since Sep 21, 2020 | Sep 21, 2020 | none ahead |
| Pfizerits history only | 10 open or running | phase 1since Mar 24, 2014 | Mar 24, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 1, 2005First study: phase 3 study in Gastroesophageal RefluxNew to Astellas PharmaAstellas Pharma · NCT00141960 · 480 enrolled · Japan
- Mar 19, 2007Amgen’s first study: phase 3 study in UlcerNew to AmgenAmgen · NCT00450216 · 906 enrolled
- Dec 3, 2008Perrigo’s first studies: 2 phase 1 studies in BioavailabilityNew to PerrigoPerrigo · NCT00803192, NCT00802828
- Feb 18, 2010Sun Pharmaceutical Industries’ first studies: 2 no phase studies in HealthyNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT01079065, NCT01079052
- Jan 12, 2012Dr. Reddy's Laboratories’ first study: phase 1 study in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01511731 · 30 enrolled · Canada
- Mar 20, 2012Phase 4 study in Arthritis, JuvenileAmgen · NCT01563185 · 12 enrolled · United States
- Mar 24, 2014Pfizer’s first study: phase 1 study in HealthyNew to PfizerPfizer · NCT02097329 · 27 enrolled · United States
- Sep 21, 2020drpykessupplements.com’s first study: phase 4 study in COVID-19New to drpykessupplements.comdrpykessupplements.com · NCT04565392 · United States
- Oct 7, 2021Leidos Life Sciences’ first studies: 3 phase 2 studies in COVID-19New to Leidos Life SciencesLeidos Life Sciences · NCT05085574, NCT05077969, NCT05077332
TargetBeta
“Histamine H2 receptor antagonist”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05085574COVID-19 | 2 | Withdrawn | Leidos Life Sciences | Feb 7, 2023 | 0 |
| NCT05077969COVID-19 · United States | 2 | Terminated | Leidos Life Sciences | Jun 28, 2022 | 4 |
| NCT05077332COVID-19 · United States | 2 | Completed | Leidos Life Sciences | Nov 10, 2025 | 4 |
| NCT04565392COVID-19 · United States | 4 | Withdrawn | drpykessupplements.com | Nov 1, 2021 | 0 |
| NCT02097329Healthy · United States | 1 | Completed | Pfizer | Jun 2014 | 27 |
| NCT01563185Arthritis, Juvenile · United States | 4 | Completed | Amgen | Mar 2015 | 12 |
| NCT01511731Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Oct 1998 | 30 |
| NCT01079065Healthy · India | – | Completed | Sun Pharmaceutical Industries | Nov 2007 | 32 |
| NCT01079052Healthy · India | – | Completed | Sun Pharmaceutical Industries | Nov 2007 | 24 |
| NCT00803192Bioavailability | 1 | Completed | Perrigo | Jun 2004 | 44 |
| NCT00802828Bioavailability | 1 | Completed | Perrigo | Jun 2004 | 44 |
| NCT00450216Ulcer | 3 | Completed | Amgen | Aug 2008 | 906 |
| NCT00141960Gastroesophageal Reflux · Japan | 3 | Completed | Astellas Pharma | 480 |
How it is read
Names in the registry
- “Famotidine”, 8 entries
- “Atazanavir+Ritonavir+Tenofovir+Famotidine”, 4 entries
- “Famotidine Tablets, 40 mg”, 2 entries
- “Atazanavir/Ritonavir + Famotidine”, 2 entries
- “Nirogacestat and Famotidine”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 4 studies
- HIV Infections, 2 studies
- Ulcer, 1 study
- Arthritis, Juvenile, 1 study
- Heartburn, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.